About Sofar
Sofar is a company based in Trezzano Rosa (Italy) founded in 1968 was acquired by Fine Foods and Pharmaceuticals NTM in April 2026. It operates as a Professional Services. Sofar has raised $52.35 thousand across 1 funding round from investors including Alfasigma and Fine Foods and Pharmaceuticals NTM. Sofar offers products and services including Pharmaceutical Production. Sofar operates in a competitive market with competitors including Jubilant Life Sciences, Recipharm, Akums, Unither and Nectar Lifesciences, among others.
- Headquarter Trezzano Rosa, Italy
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sofar S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$52.35 K (USD)
in 1 rounds
-
Latest Funding Round
$52.35 K (USD), Unspecified
May 15, 2019
-
Investors
Alfasigma
& 1 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sofar
Sofar offers a comprehensive portfolio of products and services, including Pharmaceutical Production.
Pharmaceutical products are manufactured for health sector needs.
Funding Insights of Sofar
Sofar has successfully raised a total of $52.35K through 1 strategic funding round. The most recent funding activity was a Unspecified round of $52.35 thousand completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sofar
Sofar has secured backing from 2 investors. Prominent investors backing the company include Alfasigma and Fine Foods and Pharmaceuticals NTM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Generic tablets, capsules, syrups, and injectables are manufactured.
|
Locked | Locked | Locked | |
|
Pharmaceuticals and nutraceuticals are developed and manufactured under contract.
|
Locked | Locked | Locked |
Investor details for Sofar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sofar
Investment portfolio details for Sofar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sofar
Detailed financials for Sofar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sofar Comparisons
Peer comparison for Sofar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sofar
Sofar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jubilant Life Sciences, Recipharm, Akums, Unither and Nectar Lifesciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
Cephalosporin APIs and generic formulations are manufactured.
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
Detailed competitors of Sofar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sofar
Complete news archive for Sofar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sofar
Sofar was founded in 1968 and raised its 1st funding round 51 years after it was founded.
Sofar is headquartered in Trezzano Rosa, Italy. It is registered at Trezzano Rosa, Lombardy, Italy.
Andrea Biffi is the current CEO of Sofar.
Sofar is a funded company, having raised a total of $52.35K across 1 funding round to date.
Sofar S.p.A. is focused on pharmaceutical production and operates as a Contract Development and Manufacturing Organization (CDMO). The commercial branch of Sofar S.p.A. was transferred to Alfasigma S.p.A. as of February 1, 2023. The company continues to serve the healthcare sector by providing manufacturing solutions and maintaining compliance with legal and data protection regulations.
Sofar's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Sofar offers Pharmaceutical Production.
Sofar has 2 investors. Key investors include Alfasigma, and Fine Foods and Pharmaceuticals NTM.